AFP and malignant colon neoplasm: Single or a small number of serum-based biomarkers indicative of cancer progression, such as prostate-specific antigen (PSA), alpha-fetoprotein (AFP), CA-125, CA-15.3, CA-19-9, or CEA for prostate, liver, ovary, breast, pancreas, or colon cancer, are currently used.